Backing for Japanese approval of Regnite, Ranmark and Cancidas

Keywords: Japan. XenoPort, Regnite, Horizant, Daiichi Sankyo, Ranmark, Denosumab, Merck & co, Cancidas, RLS, Bone metastatis, Antifungal

Article | 5 December 2011

USA-based XenoPort (Nasdaq: XNPT) saw its shares rise 3% to $4.73 on Friday, when the company said it has received confirmation from its partner, Astellas Pharma (TYO: 4503) that, following a meeting that day in Japan, the drug evaluation committee of the Japanese Ministry of Health, Labor and Welfare (MHLW) recommended approval of gabapentin enacarbil, which will be known by the trade name Regnite in Japan, for the treatment of Restless Legs Syndrome.

this positive recommendation will be reviewed by the MHLW prior to its final decision on authorizing the marketing of Regnite in Japan for the treatment of RLS. Enjoying this article? to continue reading you need to login, take a FREE trial or subscribe.